Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis

Back

ESC Professional Premium Access

Prognostic staging system correctly identifies high risk groups in cardiac transthyretin amyloidosis treated with tafamidis

Session: Cardiac amyloidosis: how to stage and score

Topic: Infiltrative Myocardial Disease

Speaker: Mr M. Mueller (Berlin, DE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Maximilian Mueller

Berlin (Germany)

0 follower

7 more presentations in this session

Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

Speaker: Doctor M. Llevadot Sesmilo (Badalona, ES)

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM

Speaker: Doctor R. Rettl (Vienna, AT)

Prognostic significance of right ventricular dysfunction in patients with TTR amyloidosis

Speaker: Doctor S. Istratoaie (Cluj Napoca, RO) Professor E. Donal (Rennes, FR)

Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms

Speaker: Doctor E. Oikonomou (New Haven, US)

Improving early mortality risk detection in light-chain cardiac amyloidosis patients with routine echocardiographic indicators and mayo staging

Speaker: Doctor J. Li (Beijing, CN)

Access the full session

Cardiac amyloidosis: how to stage and score

Speakers: Mr M. Mueller, Doctor M. Llevadot Sesmilo, Doctor R. Rettl, Doctor S. Istratoaie, Professor E. Donal...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources